

## Erratum

# Identification and verification of Hsp90-beta as a potential serum biomarker for lung cancer: Am J Cancer Res 2014; 4: 874-885

Biaoxue Rong<sup>1</sup>, Chongchong Zhao<sup>2</sup>, Hua Liu<sup>3</sup>, Zongjuan Ming<sup>1</sup>, Xiguang Cai<sup>3</sup>, Wenlong Gao<sup>4</sup>, Shuanying Yang<sup>1</sup>

<sup>1</sup>Department of Respiratory Medicine, Second Affiliated Hospital, Xi'an Jiaotong University, Xi'an, China; <sup>2</sup>Department of Neurology, Lanzhou University Second Hospital, Lanzhou, China; <sup>3</sup>Department of Respiratory Medicine, Gansu Provincial People's Hospital, Lanzhou, China; <sup>4</sup>Departments of Statistics and Epidemiology, Medical College, Lanzhou University, Lanzhou, China

Received February 14, 2016; Accepted February 18, 2016; Epub June 1, 2016; Published June 15, 2016

**Abstract:** Background: Hsp90-beta was investigated as prognostic factor because of its apparent association with tumorigenesis. The aim of this study was to investigate the expression of Hsp90-beta in lung cancer patients, to analyze the relationship with respect to the clinicopathological features and to assess whether Hsp90-beta as a potential serum marker for lung cancer. Methods: Expression of Hsp90-beta was examined using immunohistochemistry, in-situ hybridization, western blot and enzyme-linked immunosorbent assay. Sensitivities and specificities for Hsp90-beta serum test were determined using receiver operator characteristic curve and cutoff was defined based on 95% and 85% sensitivities. Results: Lung cancer tissues exhibited higher expression of Hsp90-beta than the normal tissues ( $P < 0.05$ ) and the serum Hsp90-beta of lung cancer patients also exhibited higher level than control groups ( $P < 0.05$ ). Moreover, increased serum Hsp90-beta was significantly associated with the pathological grade and clinical stage of lung cancer patients ( $P < 0.05$ ). Using receiver operator characteristic curve analysis, the cutoffs for distinguishing lung cancer from normal and benign groups were 1.155 and 1.158 ng/ml respectively. The sensitivities of Hsp90-beta for distinguishing lung cancer from normal and benign groups were 98.77% and 95.9%, and specificities were 88.33% and 72.7%. Conclusion: Up-regulation of serum Hsp90-beta was associated with pathological grade and clinical stage of lung cancer patients, which indicated that it could be considered molecular biomarker for diagnosis and prognosis of lung cancer.

**Keywords:** Lung cancer, serum, Hsp90-beta, biomarker, diagnosis

We apologize for spelling mistake, the correct form as follows:

**Address correspondence to:** Shuanying Yang, Department of Respiratory Medicine, Second Affiliated Hospital, Xi'an Jiaotong University, 157, Xi 5 Road, Xi'an 710004, P.R. China. Tel: (+86) 029-87678001; E-mail: yangshuanying66@126.com; yangshuanying66@163.com

### Corrections

Page	Reads	Should Read
879, Table 3, 2 rd row, 4 rd col	(pg/ml)	(ng/ml)
879, 1-3; 10, 12-16; 18-19 lines from bottom	(pg/ml)	(ng/ml)
880, 2, 4, 6, 7, 9 lines from bottom	(pg/ml)	(ng/ml)
881, 23 lines from bottom	(pg/ml)	(ng/ml)
883, 18, 23 lines from bottom	(pg/ml)	(ng/ml)